Navid Madershahian1, Maximilian Scherner2, Jochen Müller-Ehmsen3, Marcel Halbach3, Tilman Hickethier3, Ralf Velden4, Yeong-Hoon Choi2, Jens Wippermann2, Thorsten Wahlers2. 1. Department of Cardiothoracic Surgery, Cologne University Heart Centre, Kerpener Strasse 62, 50937 Cologne, Germany navid.madershahian@uk-koeln.de. 2. Department of Cardiothoracic Surgery, Cologne University Heart Centre, Kerpener Strasse 62, 50937 Cologne, Germany. 3. Department of Internal Medicine III, University of Cologne, 50937 Cologne, Germany. 4. CVRx. Inc., 9201 West Broadway Avenue, Minneapolis, MN 55445, USA.
Abstract
AIMS: The Neo™ System (CVRx) is an implantable device, CE certified for the treatment of resistant hypertension and investigationally used to treat systolic heart failure by electrical stimulation of the carotid baroreceptors. It is unknown whether interaction might exist between the Neo System and implantable cardioverter-defibrillators (ICDs). METHODS AND RESULTS: Compatibility of the Neo device was tested in seven consecutive patients with pre-existing ICDs. Intra- and post-operative testing was completed with ICD and Neo settings programmed to provoke interaction. Intracardiac electrograms were printed to determine interaction with the ICD. Interaction testing during implantation and follow-up showed that there was no device-device interaction. No interaction was observed at maximum atrial and ventricular sensitivity settings and maximum Neo output settings. CONCLUSION: Combined therapy with the Neo device and at least in this study reported that transvenous ICD systems can be performed safely. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: The Neo™ System (CVRx) is an implantable device, CE certified for the treatment of resistant hypertension and investigationally used to treat systolic heart failure by electrical stimulation of the carotid baroreceptors. It is unknown whether interaction might exist between the Neo System and implantable cardioverter-defibrillators (ICDs). METHODS AND RESULTS: Compatibility of the Neo device was tested in seven consecutive patients with pre-existing ICDs. Intra- and post-operative testing was completed with ICD and Neo settings programmed to provoke interaction. Intracardiac electrograms were printed to determine interaction with the ICD. Interaction testing during implantation and follow-up showed that there was no device-device interaction. No interaction was observed at maximum atrial and ventricular sensitivity settings and maximum Neo output settings. CONCLUSION: Combined therapy with the Neo device and at least in this study reported that transvenous ICD systems can be performed safely. Published on behalf of the European Society of Cardiology. All rights reserved.